HER2- Breast Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Breast cancer (BC) is a type of cancer that forms in breast cells, which grow and divide in an uncontrolled way, creating a mass of tissue called a tumor. Like other forms of cancer, BC can invade and grow into the tissue surrounding the breast. It can also travel to other parts of the body and form new tumors in a process called tumor metastasis. BC is one of the most common cancers diagnosed among women and is more likely to affect women over age 50 years. Women who are non-Hispanic white have a slightly higher chance of developing BC than women of any other race or ethnicity.
The HER2- Breast Cancer marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for HER2- Breast Cancer. Moreover, it analyzes the clinical and commercial landscapes of HER2- Breast Cancer, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
HER2- Breast Cancer Marketed and Pipeline Drugs Overview by Mechanism of Action
The major mechanisms of action in the HER2- Breast Cancer marketed and pipeline drugs market are enzyme inhibitor, receptor antagonist, cytotoxic, protein & peptide inhibitor, receptor agonist, receptor inhibitor, genes, nucleic acids & related components inhibitor, protein & peptide activator, biological factor inhibitor, biological factor activator, enzyme activator, antigen inhibitor, transporter inhibitor, ligand chelator, ligand depletor, genes, nucleic acids & related components activator, ion channel inhibitor, and transporter activator.
HER2- Breast Cancer Marketed and Pipeline Drugs Market Analysis by Mechanism of Action
For more mechanism of action insights, download a free report sample
HER2- Breast Cancer Marketed and Pipeline Drugs Overview by Routes of Administration
The major routes of administration in the HER2- Breast Cancer marketed and pipeline drugs market are injections, oral therapies, topical therapies, inhalational therapies, and suppository therapies.
HER2- Breast Cancer Marketed and Pipeline Drugs Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
HER2- Breast Cancer Marketed and Pipeline Drugs Market Report Overview
Major Mechanism of Action | Enzyme Inhibitor, Receptor Antagonist, Cytotoxic, Protein & Peptide Inhibitor, Receptor Agonist, Receptor Inhibitor, Genes, Nucleic Acids & Related Components Inhibitor, Protein & Peptide Activator, Biological Factor Inhibitor, Biological Factor Activator, Enzyme Activator, Antigen Inhibitor, Transporter Inhibitor, Ligand Chelator, Ligand Depletor, Genes, Nucleic Acids & Related Components Activator, Ion Channel Inhibitor, and Transporter Activator |
Major Routes of Administration | Injections, Oral Therapies, Topical Therapies, Inhalational Therapies, and Suppository Therapies |
Scope
GlobalData’s HER2- Breast Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combine data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the HER2- Breast Cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2- Breast Cancer market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the major mechanisms of action in the HER2- Breast Cancer marketed and pipeline drugs market?
The major mechanisms of action in the HER2- Breast Cancer marketed and pipeline drugs market are enzyme inhibitor, receptor antagonist, cytotoxic, protein & peptide inhibitor, receptor agonist, receptor inhibitor, genes, nucleic acids & related components inhibitor, protein & peptide activator, biological factor inhibitor, biological factor activator, enzyme activator, antigen inhibitor, transporter inhibitor, ligand chelator, ligand depletor, genes, nucleic acids & related components activator, ion channel inhibitor, and transporter activator.
-
What are the major routes of administration in the HER2- Breast Cancer marketed and pipeline drugs market?
The major routes of administration in the HER2- Breast Cancer marketed and pipeline drugs market are injections, oral therapies, topical therapies, inhalational therapies, and suppository therapies.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.